Related references
Note: Only part of the references are listed.MYC protein dysregulation is driven by BCR-PI3K signalling in diffuse large B-cell lymphoma
Wei-Ge Wang et al.
HISTOPATHOLOGY (2017)
Regulation of glucose uptake in lymphoma cell lines by cMYC-and PI3K-dependent signaling pathways and impact of glycolytic pathways on cell viability
Martina Broecker-Preuss et al.
JOURNAL OF TRANSLATIONAL MEDICINE (2017)
The B-cell receptor controls fitness of MYC-driven lymphoma cells via GSK3β inhibition
Gabriele Varano et al.
NATURE (2017)
Combination therapy in combating cancer
Reza Bayat Mokhtari et al.
ONCOTARGET (2017)
Immunomodulatory drugs target IKZF1-IRF4-MYC axis in primary effusion lymphoma in a cereblon-dependent manner and display synergistic cytotoxicity with BRD4 inhibitors
R. Gopalakrishnan et al.
ONCOGENE (2016)
MicroRNA-378 limits activation of hepatic stellate cells and liver fibrosis by suppressing Gli3 expression
Jeongeun Hyun et al.
NATURE COMMUNICATIONS (2016)
Histone deacetylase 1 plays a predominant pro-oncogenic role in Eμ-myc driven B cell lymphoma
Vincent Pillonel et al.
SCIENTIFIC REPORTS (2016)
Neuroprotective effect of the hairy root extract of Angelica gigas NAKAI on transient focal cerebral ischemia in rats through the regulation of angiogenesis
Tae Woo Oh et al.
BMC COMPLEMENTARY AND ALTERNATIVE MEDICINE (2015)
aBETting therapeutic resistance by Wnt signaling
Carl G. Engelke et al.
CELL RESEARCH (2015)
Transcriptional plasticity promotes primary and acquired resistance to BET inhibition
Philipp Rathert et al.
NATURE (2015)
BET inhibitor resistance emerges from leukaemia stem cells
Chun Yew Fong et al.
NATURE (2015)
MYC and metabolism on the path to cancer
Annie L. Hsieh et al.
SEMINARS IN CELL & DEVELOPMENTAL BIOLOGY (2015)
Novel Targeted Therapies in Diffuse Large B-Cell Lymphoma
Neha Mehta-Shah et al.
SEMINARS IN HEMATOLOGY (2015)
MCL-1 and BCL-xL-dependent resistance to the BCL-2 inhibitor ABT-199 can be overcome by preventing PI3K/AKT/mTOR activation in lymphoid malignancies
G. S. Choudhary et al.
CELL DEATH & DISEASE (2015)
Inhibition of Bromodomain Proteins for the Treatment of Human Diffuse Large B- cell Lymphoma
Sally E. Trabucco et al.
CLINICAL CANCER RESEARCH (2015)
MYC deregulation in lymphoid tumors: molecular mechanisms, clinical consequences and therapeutic implications
Tomasz Sewastianik et al.
BIOCHIMICA ET BIOPHYSICA ACTA-REVIEWS ON CANCER (2014)
Decursin prevents TPA-induced invasion through suppression of PKCα/p38/NF-κB-dependent MMP-9 expression in MCF-7 human breast carcinoma cells
Jeong-Mi Kim et al.
INTERNATIONAL JOURNAL OF ONCOLOGY (2014)
MYC protein expression and genetic alterations have prognostic impact in patients with diffuse large B-cell lymphoma treated with immunochemotherapy
Alexandra Valera et al.
HAEMATOLOGICA (2013)
Anti-cancer and Other Bioactivities of Korean Angelica gigas Nakai (AGN) and Its Major Pyranocoumarin Compounds
Jinhui Zhang et al.
ANTI-CANCER AGENTS IN MEDICINAL CHEMISTRY (2012)
The B-cell receptor signaling pathway as a therapeutic target in CLL
Jennifer A. Woyach et al.
BLOOD (2012)
Inhibitors of B-Cell Receptor Signaling for Patients With B-Cell Malignancies
Michael Y. Choi et al.
CANCER JOURNAL (2012)
BET Bromodomain Inhibition as a Therapeutic Strategy to Target c-Myc
Jake E. Delmore et al.
CELL (2011)
Decursinol angelate blocks transmigration and inflammatory activation of cancer cells through inhibition of PI3K, ERK and NF-κB activation
Won-Jung Kim et al.
CANCER LETTERS (2010)
Increased MYC gene copy number correlates with increased mRNA levels in diffuse large B-cell lymphoma
Christopher J. Stasik et al.
HAEMATOLOGICA-THE HEMATOLOGY JOURNAL (2010)
Mechanisms of Disease: Aggressive Lymphomas.
Georg Lenz et al.
NEW ENGLAND JOURNAL OF MEDICINE (2010)
Apoptosis and cancer: the genesis of a research field
Thomas G. Cotter
NATURE REVIEWS CANCER (2009)
Decursin suppresses human androgen-independent PC3 prostate cancer cell proliferation by promoting the degradation of β-catenin
Gyu-Yong Song et al.
MOLECULAR PHARMACOLOGY (2007)
Development of gas chromatographic mass spectrometry-pattern recognition method for the quality control of Korean Angelica
Xiang-Lan Piao et al.
JOURNAL OF PHARMACEUTICAL AND BIOMEDICAL ANALYSIS (2007)
c-Myc inhibition negatively impacts lymphoma growth
I Gomez-Curet et al.
JOURNAL OF PEDIATRIC SURGERY (2006)
Theoretical basis, experimental design, and computerized simulation of synergism and antagonism in drug combination studies
Ting-Chao Chou
PHARMACOLOGICAL REVIEWS (2006)
Advances in the biology and therapy of diffuse large B-cell lymphoma: moving toward a molecularly targeted approach
JS Abramson et al.
BLOOD (2005)
MCL-1 expression in B-cell non-Hodgkin's lymphomas
JH Cho-Vega et al.
HUMAN PATHOLOGY (2004)
Bcl-2 family of proteins in indolent B-cell non-Hodgkin's lymphoma: Study of 116 cases
B Agarwal et al.
AMERICAN JOURNAL OF HEMATOLOGY (2002)
Signal transduction by the JNK group of MAP kinases
RJ Davis
CELL (2000)
Distinct types of diffuse large B-cell lymphoma identified by gene expression profiling
AA Alizadeh et al.
NATURE (2000)
Share Paper
